News | May 29, 2013

Lotus Valve TAVI System Shows Good Performance in REPRISE II Trial

Report explains 30-day results.

May 29, 2013 — The Lotus Valve, a second-generation transcatheter aortic valve implantation (TAVI) device, was successfully implanted in all of the first 60 patients in results from REPRISE II, which showed good device performance and low mortality at 30 days.

"First generation TAVI devices provide significant clinical benefit, but there are opportunities for improvement," said lead author Ian Meredith, director of MonashHeart, Southern Health and professor of medicine, Monash University, Melbourne, Australia. He suggested that these include controlled deployment, simple, precise and atraumatic aortic/ventricular repositioning, no or trivial paravalvular leakage and lower complication rate.

The Lotus Valve System has been designed to address these issues. The valve is pre-attached to the delivery system, which has a simple handle design, and functions early in deployment for controlled, precise positioning. It is fully retrievable and can be repositioned and has an adaptive seal designed to minimize paravalvular leak.

REPRISE II prospectively evaluated the safety and performance of the Lotus Valve System for TAVI in symptomatic patients with severe calcific aortic stenosis considered high risk for surgical valve replacement. The primary endpoint for device performance — mean aortic valve pressure gradient at 30 days compared to a performance goal of 18 mmHg — was met. Mean aortic gradient decreased from 47.5+17.2 mmHg before the procedure to 11.3+5.2 mmHg at 30 days. At the same time effective orifice area increased from 0.6+0.2 mmHg to 1.7+0.4 mmHg.

"Results showed successful valve implantation in all 60 patients, meeting the primary device performance endpoint," Meredith said. "Importantly, the rate of moderate or greater aortic regurgitation decreased from 18 percent at the baseline study to 1.9 percent (one patient) at 30-day follow-up. More than 80 percent had either no or trivial aortic regurgitation at 30 days," he reported. He pointed out that the very low rate of moderate or greater aortic regurgitation was 10-fold lower than seen in previous trials with other systems, describing this as 'a monumental improvement. The mortality rate was low — 1.7 percent at 30 days.

"Valve repositioning and retrieval was performed successfully in all cases when required. And there was no embolization, ectopic valve deployment or TAV-in-TAV," he added. Patients suffered negligible aortic regurgitation, while other clinical event rates were consistent with those reported for other valves.

For more information:

Related Content

Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Clinical Study | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Clinical Study | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Clinical Study | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Clinical Study | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Clinical Study | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Clinical Study | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Clinical Study | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init